Johnson & Johnson posted an unusually strong 54.3% one-year return for a healthcare megacap. Profitability (A-) is solid, but growth (C) is only middling, suggesting the rally owes more to a re-rating around dividend safety than to new-product-driven growth.

As a decades-long Dividend King, its 1.93% yield and defensive character are the main draw. A ~32x P/E is somewhat rich relative to its growth grade, though, so the case here is best framed around stable income and defensiveness rather than further upside.